{"hands_on_practices": [{"introduction": "To understand chronopharmacology, we must start with the fundamental principles of how drugs interact with the body. Many drugs are weak acids or bases, and their ability to cross biological membranes is highly dependent on their ionization state, which in turn is governed by the surrounding pH. This practice [@problem_id:4933459] uses the foundational Henderson–Hasselbalch equation to demonstrate how the natural circadian rhythm of gastric pH can lead to significant time-of-day differences in the absorption of an oral drug.", "problem": "A weakly basic drug exists in equilibrium between its protonated form and its free base according to Brønsted–Lowry acid–base theory. Consider the equilibrium $$\\mathrm{BH}^{+} \\rightleftharpoons \\mathrm{B} + \\mathrm{H}^{+},$$ where the acid dissociation constant is defined by $$K_{a} = \\frac{[\\mathrm{B}][\\mathrm{H}^{+}]}{[\\mathrm{BH}^{+}]},$$ and the negative base-10 logarithm of the acid dissociation constant (denoted as pKa) is $$\\mathrm{p}K_{a} = -\\log_{10}(K_{a}).$$ For a weak base, the fraction of drug in the unionized form is determined by acid–base equilibrium and is related to the luminal hydrogen ion activity (expressed as $\\mathrm{pH}$).\n\nA patient takes an oral dose of a weakly basic drug with $\\mathrm{p}K_{a} = 7.8$. Due to circadian variation in gastric acid secretion, the mean gastric $\\mathrm{pH}$ at midday is $1.8$, while at midnight it is $3.0$. Assume the following scientifically grounded and simplified model:\n- The drug’s absorption across the gastric mucosa is the dominant contribution to its systemic input under these conditions.\n- The first-order absorption rate constant, denoted $k_{a}$, is directly proportional to the fraction of drug that is unionized in the gastric lumen at the time of dosing.\n- All other physiological and formulation factors remain constant between the two dosing times.\n\nUsing the Henderson–Hasselbalch relationship for a weak base and the definition of fraction unionized derived from fundamental acid–base equilibria, compute the predicted ratio $$\\frac{k_{a}(\\text{midnight})}{k_{a}(\\text{midday})}.$$ Express your final result as a pure number (dimensionless) and round your answer to four significant figures.", "solution": "The problem is assessed to be valid as it is scientifically grounded in the principles of acid-base chemistry and pharmacokinetics, is well-posed with a clear objective and sufficient information, and uses objective, unambiguous language. The model, while simplified, is a standard and well-established concept (the pH-partition hypothesis) used in pharmaceutical sciences.\n\nThe primary task is to compute the ratio of the first-order absorption rate constants, $k_{a}$, at midnight and midday. The problem states that $k_{a}$ is directly proportional to the fraction of the drug that is in its unionized form, denoted as $f_{u}$. This relationship can be expressed as:\n$$k_{a} = C \\cdot f_{u}$$\nwhere $C$ is a constant of proportionality. Since all other factors are assumed to be constant, $C$ is the same for both dosing times. The desired ratio is therefore:\n$$\\frac{k_{a}(\\text{midnight})}{k_{a}(\\text{midday})} = \\frac{C \\cdot f_{u}(\\text{midnight})}{C \\cdot f_{u}(\\text{midday})} = \\frac{f_{u}(\\text{midnight})}{f_{u}(\\text{midday})}$$\n\nThe next step is to derive an expression for the fraction unionized, $f_{u}$, for a weakly basic drug. The drug exists in an equilibrium between its unionized free base form, $\\mathrm{B}$, and its protonated (ionized) conjugate acid form, $\\mathrm{BH}^{+}$. The equilibrium is:\n$$\\mathrm{BH}^{+} \\rightleftharpoons \\mathrm{B} + \\mathrm{H}^{+}$$\nThe total concentration of the drug, $[\\text{Total}]$, is the sum of the concentrations of the two forms:\n$$[\\text{Total}] = [\\mathrm{B}] + [\\mathrm{BH}^{+}]$$\nThe fraction unionized, $f_{u}$, is the ratio of the concentration of the unionized form to the total drug concentration:\n$$f_{u} = \\frac{[\\mathrm{B}]}{[\\text{Total}]} = \\frac{[\\mathrm{B}]}{[\\mathrm{B}] + [\\mathrm{BH}^{+}]}$$\nTo make this expression more useful, we can divide the numerator and the denominator by $[\\mathrm{B}]$:\n$$f_{u} = \\frac{1}{1 + \\frac{[\\mathrm{BH}^{+}]}{[\\mathrm{B}]}}$$\nThe ratio $\\frac{[\\mathrm{BH}^{+}]}{[\\mathrm{B}]}$ can be determined using the Henderson–Hasselbalch equation. The acid dissociation constant for the conjugate acid $\\mathrm{BH}^{+}$ is given by:\n$$K_{a} = \\frac{[\\mathrm{B}][\\mathrm{H}^{+}]}{[\\mathrm{BH}^{+}]}$$\nTaking the negative base-10 logarithm of both sides gives:\n$$-\\log_{10}(K_{a}) = -\\log_{10}\\left(\\frac{[\\mathrm{B}][\\mathrm{H}^{+}]}{[\\mathrm{BH}^{+}]}\\right)$$\nBy definition, $\\mathrm{p}K_{a} = -\\log_{10}(K_{a})$ and $\\mathrm{pH} = -\\log_{10}([\\mathrm{H}^{+}])$. This yields the Henderson–Hasselbalch equation:\n$$\\mathrm{p}K_{a} = \\mathrm{pH} - \\log_{10}\\left(\\frac{[\\mathrm{B}]}{[\\mathrm{BH}^{+}]}\\right)$$\nRearranging to solve for the logarithm of the ratio:\n$$\\log_{10}\\left(\\frac{[\\mathrm{B}]}{[\\mathrm{BH}^{+}]}\\right) = \\mathrm{pH} - \\mathrm{p}K_{a}$$\nThis implies:\n$$\\frac{[\\mathrm{B}]}{[\\mathrm{BH}^{+}]} = 10^{\\mathrm{pH} - \\mathrm{p}K_{a}}$$\nTaking the reciprocal gives the ratio needed for the $f_{u}$ formula:\n$$\\frac{[\\mathrm{BH}^{+}]}{[\\mathrm{B}]} = 10^{-(\\mathrm{pH} - \\mathrm{p}K_{a})} = 10^{\\mathrm{p}K_{a} - \\mathrm{pH}}$$\nSubstituting this into the expression for $f_{u}$:\n$$f_{u} = \\frac{1}{1 + 10^{\\mathrm{p}K_{a} - \\mathrm{pH}}}$$\nThis is the general formula for the fraction of a weak base in its unionized form at a given $\\mathrm{p}K_{a}$ and $\\mathrm{pH}$.\n\nNow, we can apply this formula using the given values:\n- Drug $\\mathrm{p}K_{a} = 7.8$\n- Gastric $\\mathrm{pH}_{\\text{midday}} = 1.8$\n- Gastric $\\mathrm{pH}_{\\text{midnight}} = 3.0$\n\nFirst, calculate $f_{u}$ at midday:\n$$f_{u}(\\text{midday}) = \\frac{1}{1 + 10^{\\mathrm{p}K_{a} - \\mathrm{pH}_{\\text{midday}}}} = \\frac{1}{1 + 10^{7.8 - 1.8}} = \\frac{1}{1 + 10^{6.0}}$$\nNext, calculate $f_{u}$ at midnight:\n$$f_{u}(\\text{midnight}) = \\frac{1}{1 + 10^{\\mathrm{p}K_{a} - \\mathrm{pH}_{\\text{midnight}}}} = \\frac{1}{1 + 10^{7.8 - 3.0}} = \\frac{1}{1 + 10^{4.8}}$$\nFinally, we compute the ratio:\n$$\\frac{k_{a}(\\text{midnight})}{k_{a}(\\text{midday})} = \\frac{f_{u}(\\text{midnight})}{f_{u}(\\text{midday})} = \\frac{\\frac{1}{1 + 10^{4.8}}}{\\frac{1}{1 + 10^{6.0}}} = \\frac{1 + 10^{6.0}}{1 + 10^{4.8}}$$\nTo find the numerical value:\n$$10^{6.0} = 1,000,000$$\n$$10^{4.8} \\approx 63095.73$$\nThe ratio is:\n$$\\frac{1 + 1,000,000}{1 + 63095.73...} = \\frac{1,000,001}{63096.73...} \\approx 15.8489319$$\nRounding the result to four significant figures as requested gives $15.85$.", "answer": "$$\\boxed{15.85}$$", "id": "4933459"}, {"introduction": "Identifying and characterizing biological rhythms from experimental data is a core skill in chronopharmacology. Cosinor analysis is a classic and powerful statistical method used to fit a cosine function to time-series data, allowing us to quantify the rhythm's key features. This exercise [@problem_id:4527095] provides hands-on practice in applying this method to pharmacodynamic data to estimate the mean effect ($M$, or MESOR), rhythm strength ($A$, or amplitude), and time of peak effect ($\\phi$, or acrophase), and to interpret these parameters in a clinical context.", "problem": "A patient with stable daily dosing of an antihypertensive agent exhibits a circadian modulation of pharmacodynamic response due to endogenous rhythms. Assume the response over a $24$ hour period can be modeled by a single-component cosinor model with known period, with independent and identically distributed (i.i.d.) Gaussian measurement errors of known variance. Specifically, for time $t$ in hours,\n$$\nE(t) \\;=\\; M \\;+\\; A \\cos\\!\\big(\\omega t + \\phi\\big) \\;+\\; \\varepsilon(t),\n$$\nwhere $E(t)$ is a dimensionless drug-effect index, $M$ is the Midline Estimating Statistic of Rhythm (MESOR), $A$ is the amplitude, $\\phi$ is the acrophase (in radians), $\\omega = \\frac{2\\pi}{24} = \\frac{\\pi}{12}$ is the known angular frequency for a $24$ hour period, and $\\varepsilon(t)$ are i.i.d. errors with $\\varepsilon(t) \\sim \\mathcal{N}(0,\\sigma^{2})$ and known $\\sigma^{2}$. You are given eight evenly spaced observations over a full cycle at times $t_{k} = 3k$ hours for $k = 0,1,\\ldots,7$. The observed effects are:\n- $E(0) = 50 + 10\\sqrt{2}$,\n- $E(3) = 50$,\n- $E(6) = 50 - 10\\sqrt{2}$,\n- $E(9) = 30$,\n- $E(12) = 50 - 10\\sqrt{2}$,\n- $E(15) = 50$,\n- $E(18) = 50 + 10\\sqrt{2}$,\n- $E(21) = 70$.\n\nAssume the assay validation established a known error variance $\\sigma^{2} = 9$. Starting from first principles that define cosinor analysis and the trigonometric angle-addition identity, derive the linear regression representation needed to estimate $M$, $A$, and $\\phi$, obtain their point estimates from the data, and construct approximate $95\\%$ confidence intervals for these parameters using the known $\\sigma^{2}$ and the sampling scheme. Interpret the confidence intervals in the context of chronopharmacology, including the physiological meaning of the acrophase for dosing-time optimization. Finally, report the acrophase $\\phi$ in radians, rounded to four significant figures. Express the acrophase in radians.", "solution": "The problem statement is evaluated as scientifically grounded, well-posed, objective, and complete. All necessary data, models, and constants are provided to derive a unique and meaningful solution. The methodology, cosinor analysis via linear regression, is a standard and valid technique in chronopharmacology. The problem is therefore deemed valid.\n\nThe solution proceeds in four stages:\n1.  Linearization of the nonlinear cosinor model into a multiple linear regression form.\n2.  Estimation of the linear model parameters using the method of least squares.\n3.  Transformation of the linear parameter estimates back into the original cosinor parameters ($M$, $A$, $\\phi$).\n4.  Construction and interpretation of approximate $95\\%$ confidence intervals for the cosinor parameters.\n\n**1. Derivation of the Linear Regression Representation**\n\nThe given single-component cosinor model is:\n$$\nE(t) = M + A \\cos(\\omega t + \\phi) + \\varepsilon(t)\n$$\nThis model is nonlinear in the parameters $A$ and $\\phi$. To estimate these parameters using linear regression, we first linearize the model. We use the trigonometric angle-addition identity $\\cos(x+y) = \\cos(x)\\cos(y) - \\sin(x)\\sin(y)$. Applying this to the cosine term gives:\n$$\nA \\cos(\\omega t + \\phi) = A (\\cos(\\omega t)\\cos(\\phi) - \\sin(\\omega t)\\sin(\\phi))\n$$\n$$\nA \\cos(\\omega t + \\phi) = (A\\cos(\\phi))\\cos(\\omega t) + (-A\\sin(\\phi))\\sin(\\omega t)\n$$\nWe define two new parameters, $b_1$ and $b_2$, as:\n$$\nb_1 = A\\cos(\\phi)\n$$\n$$\nb_2 = -A\\sin(\\phi)\n$$\nSubstituting these back into the original model, we obtain a model that is linear in the parameters $M$, $b_1$, and $b_2$:\n$$\nE(t) = M + b_1 \\cos(\\omega t) + b_2 \\sin(\\omega t) + \\varepsilon(t)\n$$\nThis is a multiple linear regression model. For a set of $N$ observations $E(t_k)$ at times $t_k$, the model can be written in matrix form as $Y = X\\beta + \\epsilon$, where:\n$Y = \\begin{pmatrix} E(t_0) \\\\ \\vdots \\\\ E(t_{N-1}) \\end{pmatrix}$, $X = \\begin{pmatrix} 1 & \\cos(\\omega t_0) & \\sin(\\omega t_0) \\\\ \\vdots & \\vdots & \\vdots \\\\ 1 & \\cos(\\omega t_{N-1}) & \\sin(\\omega t_{N-1}) \\end{pmatrix}$, $\\beta = \\begin{pmatrix} M \\\\ b_1 \\\\ b_2 \\end{pmatrix}$, $\\epsilon = \\begin{pmatrix} \\varepsilon(t_0) \\\\ \\vdots \\\\ \\varepsilon(t_{N-1}) \\end{pmatrix}$.\n\n**2. Least Squares Estimation of Linear Parameters**\n\nThe least squares estimate for the parameter vector $\\beta$ is given by $\\hat{\\beta} = (X^T X)^{-1} X^T Y$. The problem specifies $N=8$ observations at times $t_k = 3k$ for $k=0, 1, \\dots, 7$. The angular frequency is $\\omega = \\frac{\\pi}{12}$ rad/hr. Thus, the argument of the trigonometric functions is $\\omega t_k = \\frac{\\pi}{12} (3k) = \\frac{k\\pi}{4}$.\n\nThe design matrix $X$ is populated by columns that are orthogonal due to the symmetric sampling over a full cycle. Let's verify the sums that form the matrix $X^T X$:\n$\\sum_{k=0}^{7} 1 = N = 8$\n$\\sum_{k=0}^{7} \\cos(\\frac{k\\pi}{4}) = 1 + \\frac{\\sqrt{2}}{2} + 0 - \\frac{\\sqrt{2}}{2} - 1 - \\frac{\\sqrt{2}}{2} + 0 + \\frac{\\sqrt{2}}{2} = 0$\n$\\sum_{k=0}^{7} \\sin(\\frac{k\\pi}{4}) = 0 + \\frac{\\sqrt{2}}{2} + 1 + \\frac{\\sqrt{2}}{2} + 0 - \\frac{\\sqrt{2}}{2} - 1 - \\frac{\\sqrt{2}}{2} = 0$\n$\\sum_{k=0}^{7} \\cos(\\frac{k\\pi}{4})\\sin(\\frac{k\\pi}{4}) = \\frac{1}{2}\\sum_{k=0}^{7} \\sin(\\frac{k\\pi}{2}) = \\frac{1}{2}(0+1+0-1+0+1+0-1) = 0$\n$\\sum_{k=0}^{7} \\cos^2(\\frac{k\\pi}{4}) = 1^2 + (\\frac{\\sqrt{2}}{2})^2 + 0^2 + (-\\frac{\\sqrt{2}}{2})^2 + (-1)^2 + (-\\frac{\\sqrt{2}}{2})^2 + 0^2 + (\\frac{\\sqrt{2}}{2})^2 = 1+\\frac{1}{2}+0+\\frac{1}{2}+1+\\frac{1}{2}+0+\\frac{1}{2} = 4 = \\frac{N}{2}$\n$\\sum_{k=0}^{7} \\sin^2(\\frac{k\\pi}{4}) = 0^2 + (\\frac{\\sqrt{2}}{2})^2 + 1^2 + (\\frac{\\sqrt{2}}{2})^2 + 0^2 + (-\\frac{\\sqrt{2}}{2})^2 + (-1)^2 + (-\\frac{\\sqrt{2}}{2})^2 = 0+\\frac{1}{2}+1+\\frac{1}{2}+0+\\frac{1}{2}+1+\\frac{1}{2} = 4 = \\frac{N}{2}$\n\nTherefore, $X^T X$ is a diagonal matrix:\n$$\nX^T X = \\begin{pmatrix} 8 & 0 & 0 \\\\ 0 & 4 & 0 \\\\ 0 & 0 & 4 \\end{pmatrix}\n$$\nIts inverse is simply:\n$$\n(X^T X)^{-1} = \\begin{pmatrix} 1/8 & 0 & 0 \\\\ 0 & 1/4 & 0 \\\\ 0 & 0 & 1/4 \\end{pmatrix}\n$$\nNext, we compute $X^T Y$:\n$\\sum_{k=0}^{7} E(t_k) = (50+10\\sqrt{2}) + 50 + (50-10\\sqrt{2}) + 30 + (50-10\\sqrt{2}) + 50 + (50+10\\sqrt{2}) + 70 = 400$\n$\\sum_{k=0}^{7} E(t_k)\\cos(\\omega t_k) = 1(50+10\\sqrt{2}) + \\frac{\\sqrt{2}}{2}(50) + 0 - \\frac{\\sqrt{2}}{2}(30) - 1(50-10\\sqrt{2}) - \\frac{\\sqrt{2}}{2}(50) + 0 + \\frac{\\sqrt{2}}{2}(70) = 50+10\\sqrt{2} + 25\\sqrt{2} - 15\\sqrt{2} - 50+10\\sqrt{2} - 25\\sqrt{2} + 35\\sqrt{2} = 40\\sqrt{2}$\n$\\sum_{k=0}^{7} E(t_k)\\sin(\\omega t_k) = 0 + \\frac{\\sqrt{2}}{2}(50) + 1(50-10\\sqrt{2}) + \\frac{\\sqrt{2}}{2}(30) + 0 - \\frac{\\sqrt{2}}{2}(50) - 1(50+10\\sqrt{2}) - \\frac{\\sqrt{2}}{2}(70) = 25\\sqrt{2} + 50-10\\sqrt{2} + 15\\sqrt{2} - 25\\sqrt{2} - 50-10\\sqrt{2} - 35\\sqrt{2} = -40\\sqrt{2}$\n\nSo, $X^T Y = \\begin{pmatrix} 400 \\\\ 40\\sqrt{2} \\\\ -40\\sqrt{2} \\end{pmatrix}$.\nThe estimated linear parameter vector is:\n$$\n\\hat{\\beta} = \\begin{pmatrix} \\hat{M} \\\\ \\hat{b}_1 \\\\ \\hat{b}_2 \\end{pmatrix} = (X^T X)^{-1} X^T Y = \\begin{pmatrix} 1/8 & 0 & 0 \\\\ 0 & 1/4 & 0 \\\\ 0 & 0 & 1/4 \\end{pmatrix} \\begin{pmatrix} 400 \\\\ 40\\sqrt{2} \\\\ -40\\sqrt{2} \\end{pmatrix} = \\begin{pmatrix} 50 \\\\ 10\\sqrt{2} \\\\ -10\\sqrt{2} \\end{pmatrix}\n$$\nThus, the point estimates are $\\hat{M}=50$, $\\hat{b}_1=10\\sqrt{2}$, and $\\hat{b}_2=-10\\sqrt{2}$.\n\n**3. Transformation to Cosinor Parameters**\n\nWe now transform $\\hat{b}_1$ and $\\hat{b}_2$ back to estimates for $A$ and $\\phi$. From the definitions $b_1 = A\\cos(\\phi)$ and $b_2 = -A\\sin(\\phi)$:\n$$\nA = \\sqrt{b_1^2 + b_2^2} \\implies \\hat{A} = \\sqrt{\\hat{b}_1^2 + \\hat{b}_2^2} = \\sqrt{(10\\sqrt{2})^2 + (-10\\sqrt{2})^2} = \\sqrt{200 + 200} = \\sqrt{400} = 20\n$$\nFor the acrophase $\\phi$, we have $\\cos(\\phi) = b_1/A$ and $\\sin(\\phi) = -b_2/A$.\n$$\n\\cos(\\hat{\\phi}) = \\frac{\\hat{b}_1}{\\hat{A}} = \\frac{10\\sqrt{2}}{20} = \\frac{\\sqrt{2}}{2}\n$$\n$$\n\\sin(\\hat{\\phi}) = \\frac{-\\hat{b}_2}{\\hat{A}} = \\frac{-(-10\\sqrt{2})}{20} = \\frac{\\sqrt{2}}{2}\n$$\nSince both sine and cosine are positive, $\\hat{\\phi}$ is in the first quadrant.\n$$\n\\hat{\\phi} = \\arccos\\left(\\frac{\\sqrt{2}}{2}\\right) = \\frac{\\pi}{4} \\text{ radians}\n$$\nThe point estimates for the cosinor parameters are $\\hat{M}=50$, $\\hat{A}=20$, and $\\hat{\\phi}=\\pi/4$.\n\n**4. Confidence Intervals and Interpretation**\n\nThe variance of the estimator $\\hat{\\beta}$ is $\\text{Var}(\\hat{\\beta}) = \\sigma^2 (X^T X)^{-1}$, where the error variance $\\sigma^2=9$ is given as known.\n$$\n\\text{Var}(\\hat{\\beta}) = 9 \\begin{pmatrix} 1/8 & 0 & 0 \\\\ 0 & 1/4 & 0 \\\\ 0 & 0 & 1/4 \\end{pmatrix} = \\begin{pmatrix} 9/8 & 0 & 0 \\\\ 0 & 9/4 & 0 \\\\ 0 & 0 & 9/4 \\end{pmatrix}\n$$\nThis gives the variances of the linear parameters: $\\text{Var}(\\hat{M})=9/8$, $\\text{Var}(\\hat{b}_1)=9/4$, and $\\text{Var}(\\hat{b}_2)=9/4$.\nFor a $95\\%$ confidence interval with known variance, we use the z-score $z_{0.025} = 1.96$.\n\n*   **Confidence Interval for M (MESOR):**\n    $$\n    CI_M = \\hat{M} \\pm z_{0.025} \\sqrt{\\text{Var}(\\hat{M})} = 50 \\pm 1.96 \\sqrt{9/8} = 50 \\pm 1.96 \\frac{3}{2\\sqrt{2}} \\approx 50 \\pm 2.079\n    $$\n    $CI_M = [47.92, 52.08]$. We are $95\\%$ confident the true mean drug effect lies in this interval.\n\n*   **Confidence Interval for A (Amplitude):**\n    We use the Delta method for the variance of $\\hat{A} = \\sqrt{\\hat{b}_1^2 + \\hat{b}_2^2}$. Since $\\text{Cov}(\\hat{b}_1, \\hat{b}_2)=0$:\n    $$\n    \\text{Var}(\\hat{A}) \\approx \\left(\\frac{\\partial A}{\\partial b_1}\\right)^2 \\text{Var}(\\hat{b}_1) + \\left(\\frac{\\partial A}{\\partial b_2}\\right)^2 \\text{Var}(\\hat{b}_2) = \\left(\\frac{b_1}{A}\\right)^2 \\text{Var}(\\hat{b}_1) + \\left(\\frac{b_2}{A}\\right)^2 \\text{Var}(\\hat{b}_2)\n    $$\n    Evaluated at the estimates:\n    $$\n    \\text{Var}(\\hat{A}) \\approx \\left(\\frac{10\\sqrt{2}}{20}\\right)^2 \\frac{9}{4} + \\left(\\frac{-10\\sqrt{2}}{20}\\right)^2 \\frac{9}{4} = \\left(\\frac{1}{2}\\right)\\frac{9}{4} + \\left(\\frac{1}{2}\\right)\\frac{9}{4} = \\frac{9}{4}\n    $$\n    $$\n    CI_A = \\hat{A} \\pm z_{0.025} \\sqrt{\\text{Var}(\\hat{A})} = 20 \\pm 1.96 \\sqrt{9/4} = 20 \\pm 1.96(1.5) = 20 \\pm 2.94\n    $$\n    $CI_A = [17.06, 22.94]$. Since this interval does not contain $0$, the circadian rhythm is statistically significant.\n\n*   **Confidence Interval for $\\phi$ (Acrophase):**\n    Using the Delta method for $\\hat{\\phi} = \\arctan(- \\hat{b}_2 / \\hat{b}_1)$:\n    $$\n    \\text{Var}(\\hat{\\phi}) \\approx \\left(\\frac{\\partial \\phi}{\\partial b_1}\\right)^2 \\text{Var}(\\hat{b}_1) + \\left(\\frac{\\partial \\phi}{\\partial b_2}\\right)^2 \\text{Var}(\\hat{b}_2) = \\left(\\frac{b_2}{A^2}\\right)^2 \\text{Var}(\\hat{b}_1) + \\left(\\frac{-b_1}{A^2}\\right)^2 \\text{Var}(\\hat{b}_2)\n    $$\n    $$\n    \\text{Var}(\\hat{\\phi}) \\approx \\frac{1}{A^4} (b_2^2 \\text{Var}(\\hat{b}_1) + b_1^2 \\text{Var}(\\hat{b}_2)) = \\frac{b_1^2+b_2^2}{A^4} \\text{Var}(\\hat{b}_1) = \\frac{A^2}{A^4} \\text{Var}(\\hat{b}_1) = \\frac{\\text{Var}(\\hat{b}_1)}{A^2}\n    $$\n    Evaluated at the estimates:\n    $$\n    \\text{Var}(\\hat{\\phi}) \\approx \\frac{9/4}{20^2} = \\frac{9}{1600}\n    $$\n    $$\n    CI_\\phi = \\hat{\\phi} \\pm z_{0.025} \\sqrt{\\text{Var}(\\hat{\\phi})} = \\frac{\\pi}{4} \\pm 1.96 \\sqrt{\\frac{9}{1600}} = \\frac{\\pi}{4} \\pm 1.96 \\frac{3}{40} = \\frac{\\pi}{4} \\pm 0.147\n    $$\n    $CI_\\phi \\approx 0.7854 \\pm 0.147 = [0.638, 0.932]$ radians.\n\n**Interpretation in Chronopharmacology:**\nThe acrophase, $\\phi$, quantifies the timing of the peak of the circadian rhythm. The peak effect occurs at time $t_{peak}$ when the argument of the cosine is zero: $\\omega t_{peak} + \\phi = 0$.\n$$\nt_{peak} = -\\frac{\\phi}{\\omega} = -\\frac{\\pi/4}{\\pi/12} = -3 \\text{ hours}\n$$\nIn a $24$-hour cycle, this corresponds to $t_{peak} = 21$ hours, or $9$ PM. The minimum effect occurs $\\pi$ radians ($12$ hours) later at $t_{trough} = 9$ hours, or $9$ AM. For an antihypertensive agent, a larger effect index likely means greater blood pressure reduction. This patient's drug regimen results in the strongest effect in the evening and the weakest effect in the morning.\nThis information is critical for dosing-time optimization. Many hypertensive patients experience a \"morning surge\" in blood pressure, a period of high cardiovascular risk. The finding that the drug's effect is at its nadir at $9$ AM suggests the current dosing schedule may be suboptimal for controlling this surge. A clinician might use this acrophase information to recommend shifting the dosing time (e.g., to the evening) to better align the peak drug effect with the time of greatest physiological need, thereby improving therapeutic outcomes. The confidence interval for $\\phi$ quantifies the statistical certainty of this timing.\n\nThe final requested value is the acrophase $\\phi$ in radians, rounded to four significant figures.\n$\\hat{\\phi} = \\frac{\\pi}{4} \\approx 0.785398...$\nRounded to four significant figures, this is $0.7854$.", "answer": "$$\\boxed{0.7854}$$", "id": "4527095"}, {"introduction": "The ultimate goal of chronopharmacology is to optimize therapy by timing drug administration to the body's internal clocks. This often requires integrating models of how the body handles a drug (pharmacokinetics, or PK) with models of the drug's effect, which may itself vary rhythmically (pharmacodynamics, or PD). This final practice [@problem_id:4933385] challenges you to construct an integrated PK-PD model for the anti-inflammatory drug prednisone, accounting for its absorption, elimination, and the circadian sensitivity of its target receptors, to solve the clinically relevant problem of timing a dose to maximize its effect when it is needed most.", "problem": "A clinician wants to time an oral prednisone dose so that the pharmacodynamic anti-inflammatory effect aligns with the early-morning peak in disease activity. Build a minimal pharmacokinetic–pharmacodynamic (PK–PD) model grounded on standard compartmental pharmacokinetics and receptor theory, and use it to determine the optimal dosing time that maximizes anti-inflammatory effect at a specified clock time.\n\nAssume the following scientifically supported modeling primitives and parameters:\n- Pharmacokinetics: A single oral immediate-release dose of prednisone is administered at clock-time $t_{\\text{dose}}$ (hours after midnight). After administration, drug in the gastrointestinal tract follows first-order absorption with absorption rate constant $k_{a}$ into a single central compartment. The active moiety in plasma (prednisolone) is eliminated with first-order rate constant $k_{e}$. The oral bioavailability is $F$, the apparent volume of distribution is $V$, and the dose is $D$. Let $A_{g}(t)$ be the amount in the gut and $A_{c}(t)$ be the amount in the central compartment. Use linear, time-invariant dynamics and assume instantaneous linear disposition in the central compartment. \n- Bioconversion lag: Hepatic conversion from prednisone to prednisolone imposes a fixed effect-site delay $\\tau_{c}$ between plasma concentration and onset of pharmacodynamic effect.\n- Pharmacodynamics: In the low-occupancy regime of receptor theory, assume a linear link between effect and the product of active concentration and a time-varying glucocorticoid receptor (GR) sensitivity factor. Let the effect be $E(t) = \\alpha\\,S(t)\\,C_{\\text{act}}(t)$, where $\\alpha$ is a proportionality constant, $S(t)$ is the circadian GR sensitivity, and $C_{\\text{act}}(t)$ is the active prednisolone concentration at the effect site.\n- Circadian GR sensitivity: Model GR sensitivity as a $24$-hour sinusoid, $S(t) = 1 + A\\cos\\!\\left( \\frac{2\\pi}{24}\\left(t-\\phi\\right) \\right)$, with amplitude $A$ and phase $\\phi$ (both in hours). Clock-time $t$ is measured in hours after midnight.\n- Clinical need: The anti-inflammatory need peaks at $t_{\\text{need}} = 5$ hours after midnight, and the practical goal is to maximize the instantaneous effect $E(t)$ at $t=t_{\\text{need}}$ by choosing $t_{\\text{dose}}$.\n\nUse the following parameter values: $D = 20$ (milligrams), $F = 0.8$, $V = 50$ (liters), $k_{a} = 1.2$ (hour$^{-1}$), $k_{e} = 0.25$ (hour$^{-1}$), $\\tau_{c} = 0.5$ (hours), $A = 0.3$, and $\\phi = 4$ (hours). Assume $k_{a} \\neq k_{e}$ and that $t_{\\text{need}} > t_{\\text{dose}}$ so that the post-dose dynamics apply without wraparound; if your calculated $t_{\\text{dose}}$ is negative or exceeds $24$, interpret it modulo $24$.\n\nTasks:\n1. Starting from mass balance and first-order kinetics, write down the concentration–time profile $C(t)$ in the central compartment after a single oral dose at $t=0$. Then incorporate the dosing time $t_{\\text{dose}}$ and the effect-site delay $\\tau_{c}$ to obtain $C_{\\text{act}}(t)$.\n2. Using the linear low-occupancy PD link and the circadian $S(t)$ given, express the instantaneous effect $E(t)$ at $t = t_{\\text{need}}$ as a function of $t_{\\text{dose}}$.\n3. Determine the value of $t_{\\text{dose}}$ (in hours after midnight) that maximizes $E(t_{\\text{need}})$ under the given assumptions and parameters.\n\nRound your final numerical answer for $t_{\\text{dose}}$ to $4$ significant figures. Express the answer in hours after midnight (do not include units in the final boxed answer).", "solution": "The problem requires the determination of an optimal drug dosing time, $t_{\\text{dose}}$, to maximize an anti-inflammatory effect at a specific time of day, $t_{\\text{need}}$. This is a problem in chronopharmacology that can be solved by constructing and analyzing a pharmacokinetic-pharmacodynamic (PK-PD) model based on the provided principles. The solution is structured into three parts as requested by the tasks.\n\n### Task 1: Derivation of the Active Concentration Profile, $C_{\\text{act}}(t)$\n\nFirst, we establish the pharmacokinetic model for the concentration of the active drug moiety (prednisolone) in the central compartment (plasma). The model is a one-compartment model with first-order absorption and first-order elimination.\n\nLet $A_{g}(t)$ be the amount of drug in the gastrointestinal (GI) tract and $A_{c}(t)$ be the amount of drug in the central compartment at time $t$. The dynamics are described by the following system of linear first-order ordinary differential equations, derived from mass balance principles:\n$$\n\\frac{dA_{g}(t)}{dt} = -k_{a} A_{g}(t)\n$$\n$$\n\\frac{dA_{c}(t)}{dt} = k_{a} A_{g}(t) - k_{e} A_{c}(t)\n$$\nHere, $k_{a}$ is the absorption rate constant and $k_{e}$ is the elimination rate constant.\n\nConsider a single oral dose $D$ administered at time $t=0$. The amount of drug that enters the GI tract is limited by the oral bioavailability, $F$. Thus, the initial conditions are:\n$$\nA_{g}(0) = F D\n$$\n$$\nA_{c}(0) = 0\n$$\nSolving the first differential equation for $A_{g}(t)$ is straightforward:\n$$\nA_{g}(t) = A_{g}(0) \\exp(-k_{a} t) = F D \\exp(-k_{a} t)\n$$\nSubstituting this into the second equation gives:\n$$\n\\frac{dA_{c}(t)}{dt} + k_{e} A_{c}(t) = k_{a} F D \\exp(-k_{a} t)\n$$\nThis is a linear first-order non-homogeneous differential equation. Using an integrating factor, $\\mu(t) = \\exp(\\int k_e dt) = \\exp(k_e t)$, the solution is:\n$$\nA_{c}(t) = \\frac{1}{\\mu(t)} \\left( \\int \\mu(t) k_{a} F D \\exp(-k_{a} t) dt + C \\right)\n$$\n$$\nA_{c}(t) = \\exp(-k_{e} t) \\left( k_{a} F D \\int \\exp(k_{e} t) \\exp(-k_{a} t) dt + C \\right)\n$$\n$$\nA_{c}(t) = \\exp(-k_{e} t) \\left( k_{a} F D \\int \\exp((k_{e}-k_{a})t) dt + C \\right)\n$$\nSince $k_{a} \\neq k_{e}$ is given, the integral evaluates to:\n$$\nA_{c}(t) = \\exp(-k_{e} t) \\left( \\frac{k_{a} F D}{k_{e}-k_{a}} \\exp((k_{e}-k_{a})t) + C \\right) = \\frac{k_{a} F D}{k_{e}-k_{a}} \\exp(-k_{a} t) + C \\exp(-k_{e} t)\n$$\nApplying the initial condition $A_{c}(0)=0$:\n$$\n0 = \\frac{k_{a} F D}{k_{e}-k_{a}} + C \\implies C = -\\frac{k_{a} F D}{k_{e}-k_{a}} = \\frac{k_{a} F D}{k_{a}-k_{e}}\n$$\nSubstituting $C$ back into the expression for $A_{c}(t)$:\n$$\nA_{c}(t) = \\frac{k_{a} F D}{k_{a}-k_{e}} \\left( \\exp(-k_{e} t) - \\exp(-k_{a} t) \\right)\n$$\nThe concentration in the central compartment, $C(t)$, is the amount divided by the apparent volume of distribution, $V$:\n$$\nC(t) = \\frac{A_{c}(t)}{V} = \\frac{F D k_{a}}{V(k_{a}-k_{e})} \\left( \\exp(-k_{e} t) - \\exp(-k_{a} t) \\right)\n$$\nThis is the Bateman function for a dose administered at $t=0$. If the dose is administered at $t=t_{\\text{dose}}$, the time course is shifted. For $t > t_{\\text{dose}}$, we replace $t$ with $(t-t_{\\text{dose}})$:\n$$\nC(t; t_{\\text{dose}}) = \\frac{F D k_{a}}{V(k_{a}-k_{e})} \\left( \\exp(-k_{e}(t-t_{\\text{dose}})) - \\exp(-k_{a}(t-t_{\\text{dose}})) \\right)\n$$\nThe problem states there is a bioconversion lag $\\tau_{c}$ between plasma concentration and the effect site. Thus, the active concentration at the effect site at time $t$, denoted $C_{\\text{act}}(t)$, is equal to the plasma concentration at time $t-\\tau_{c}$. This is valid for $t > t_{\\text{dose}} + \\tau_c$.\n$$\nC_{\\text{act}}(t) = C(t-\\tau_{c}; t_{\\text{dose}}) = \\frac{F D k_{a}}{V(k_{a}-k_{e})} \\left( \\exp(-k_{e}(t-t_{\\text{dose}}-\\tau_{c})) - \\exp(-k_{a}(t-t_{\\text{dose}}-\\tau_{c})) \\right)\n$$\n\n### Task 2: Expression for the Effect $E(t_{\\text{need}})$\n\nThe pharmacodynamic effect $E(t)$ is given by the linear model:\n$$\nE(t) = \\alpha S(t) C_{\\text{act}}(t)\n$$\nwhere $\\alpha$ is a proportionality constant, and $S(t)$ is the circadian sensitivity of the glucocorticoid receptors (GR), given by:\n$$\nS(t) = 1 + A\\cos\\left(\\frac{2\\pi}{24}(t-\\phi)\\right)\n$$\nWe need to find the effect at the specific time of clinical need, $t = t_{\\text{need}}$. By substituting the expressions for $S(t)$ and $C_{\\text{act}}(t)$ at $t=t_{\\text{need}}$, we obtain:\n$$\nE(t_{\\text{need}}) = \\alpha \\left[ 1 + A\\cos\\left(\\frac{2\\pi}{24}(t_{\\text{need}}-\\phi)\\right) \\right] \\left[ \\frac{F D k_{a}}{V(k_{a}-k_{e})} \\left( \\exp(-k_{e}(t_{\\text{need}}-t_{\\text{dose}}-\\tau_{c})) - \\exp(-k_{a}(t_{\\text{need}}-t_{\\text{dose}}-\\tau_{c})) \\right) \\right]\n$$\nThis expression gives the instantaneous effect at $t=t_{\\text{need}}$ as a function of the dosing time $t_{\\text{dose}}$.\n\n### Task 3: Determination of the Optimal Dosing Time $t_{\\text{dose}}$\n\nThe goal is to find the value of $t_{\\text{dose}}$ that maximizes $E(t_{\\text{need}})$. Let's examine the expression for $E(t_{\\text{need}})$. It is a product of several terms. The terms $\\alpha$, $F$, $D$, $V$, $k_a$, $k_e$ are positive constants. The term involving the circadian sensitivity, $S(t_{\\text{need}}) = 1 + A\\cos(\\frac{2\\pi}{24}(t_{\\text{need}}-\\phi))$, is also a constant because $t_{\\text{need}}$ is fixed. Since $A=0.3 < 1$, $S(t_{\\text{need}})$ is always positive.\n\nTherefore, maximizing $E(t_{\\text{need}})$ is equivalent to maximizing the part of the expression that depends on $t_{\\text{dose}}$:\n$$\nf(t_{\\text{dose}}) = \\exp(-k_{e}(t_{\\text{need}}-t_{\\text{dose}}-\\tau_{c})) - \\exp(-k_{a}(t_{\\text{need}}-t_{\\text{dose}}-\\tau_{c}))\n$$\nTo find the maximum, we take the derivative of $f(t_{\\text{dose}})$ with respect to $t_{\\text{dose}}$ and set it to zero. Let $\\Delta t = t_{\\text{need}}-t_{\\text{dose}}-\\tau_{c}$. Then $f(t_{\\text{dose}}) = \\exp(-k_e \\Delta t) - \\exp(-k_a \\Delta t)$. Note that $\\frac{d(\\Delta t)}{d t_{\\text{dose}}} = -1$.\nUsing the chain rule:\n$$\n\\frac{df}{dt_{\\text{dose}}} = \\frac{d}{dt_{\\text{dose}}} \\left[ \\exp(-k_{e}\\Delta t) - \\exp(-k_{a}\\Delta t) \\right]\n$$\n$$\n\\frac{df}{dt_{\\text{dose}}} = -k_{e}\\exp(-k_{e}\\Delta t) \\cdot (-1) - (-k_{a})\\exp(-k_{a}\\Delta t) \\cdot (-1)\n$$\n$$\n\\frac{df}{dt_{\\text{dose}}} = k_{e}\\exp(-k_{e}\\Delta t) - k_{a}\\exp(-k_{a}\\Delta t)\n$$\nSet the derivative to zero:\n$$\nk_{e}\\exp(-k_{e}\\Delta t) = k_{a}\\exp(-k_{a}\\Delta t)\n$$\nRearranging the terms to solve for $\\Delta t$:\n$$\n\\frac{k_{a}}{k_{e}} = \\frac{\\exp(-k_{e}\\Delta t)}{\\exp(-k_{a}\\Delta t)} = \\exp((k_{a}-k_{e})\\Delta t)\n$$\nTaking the natural logarithm of both sides:\n$$\n\\ln\\left(\\frac{k_{a}}{k_{e}}\\right) = (k_{a}-k_{e})\\Delta t\n$$\n$$\n\\Delta t = \\frac{\\ln(k_{a}/k_{e})}{k_{a}-k_{e}}\n$$\nThis value of $\\Delta t$ corresponds to the time required to reach peak concentration after oral administration, often denoted $t_{\\text{max}}$.\nNow, we substitute back $\\Delta t = t_{\\text{need}}-t_{\\text{dose}}-\\tau_{c}$ and solve for $t_{\\text{dose}}$:\n$$\nt_{\\text{need}}-t_{\\text{dose}}-\\tau_{c} = \\frac{\\ln(k_{a}/k_{e})}{k_{a}-k_{e}}\n$$\n$$\nt_{\\text{dose}} = t_{\\text{need}} - \\tau_{c} - \\frac{\\ln(k_{a}/k_{e})}{k_{a}-k_{e}}\n$$\nThe second derivative test confirms this is a maximum, as the concentration profile has a single peak.\n\nNow, we substitute the given parameter values:\n$t_{\\text{need}} = 5$ hr\n$\\tau_{c} = 0.5$ hr\n$k_{a} = 1.2$ hr$^{-1}$\n$k_{e} = 0.25$ hr$^{-1}$\n\nFirst, calculate the time-to-peak component:\n$$\n\\frac{\\ln(k_{a}/k_{e})}{k_{a}-k_{e}} = \\frac{\\ln(1.2/0.25)}{1.2-0.25} = \\frac{\\ln(4.8)}{0.95}\n$$\nUsing the natural logarithm $\\ln(4.8) \\approx 1.5686159$:\n$$\n\\frac{1.5686159}{0.95} \\approx 1.6511746 \\text{ hr}\n$$\nNow, calculate $t_{\\text{dose}}$:\n$$\nt_{\\text{dose}} = 5 - 0.5 - 1.6511746 = 4.5 - 1.6511746 = 2.8488254 \\text{ hr}\n$$\nThe problem asks to round the final answer to $4$ significant figures.\n$$\nt_{\\text{dose}} \\approx 2.849 \\text{ hr}\n$$\nThis value is in hours after midnight, as required. The result satisfies the assumption $t_{\\text{need}} > t_{\\text{dose}}$ ($5 > 2.849$).", "answer": "$$\n\\boxed{2.849}\n$$", "id": "4933385"}]}